The company has sought FDA approval to expand the use of its hepatitis B
vaccine Heplisav-B for adults on hemodialysis and a decision is due on
May 13, 2024.
The Heplisav-B vaccine, which combines hepatitis B surface antigen with
Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist adjuvant CpG
1018, was approved by the FDA in November 2017, for prevention of
infection caused by all known subtypes of hepatitis B virus in adults of
age 18 years and older.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com